Sen Nesrin, Kacar Cahit, Ozdem Sebahat, Uzun Gulbahar, Tezcan Mehmet Engin
Department of Rheumatology, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, Turkiye.
Department of Physical Medicine Rehabilitation and Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkiye.
North Clin Istanb. 2023 Jun 22;10(3):328-334. doi: 10.14744/nci.2022.39225. eCollection 2023.
Ankylosing spondylitis (AS) is a rheumatologic disease with severe morbidity and mortality. Many studies in the literature showing that serum antibodies against anti-mutated citrullinated vimentin (anti-MCV ab) can be elevated in rheumatoid arthritis (RA) patients. However, there is little data in the literature about the levels of anti-MCV antibodies in AS patients. We designed the study to evaluate the role of anti-MCV antibody in the diagnosis of AS and to investigate whether it is associated with disease activity parameters.
There were three separate groups in our study. The number of participants in these groups is 60 patients in the AS group, 60 patients in the RA group, and 50 healthy participants in the control group. The anti-MCV ab levels of the participants were measured by enzyme-like immune assay method. We compared anti-MCV levels between groups. We then evaluated its role in the diagnosis of AS and evaluated its relationship with disease activity parameters.
The anti-MCV antibody levels of both AS (p=0.006) and RA (p>0.001) patients were found to be significantly higher than controls. Anti-MCV antibody was higher than predefined threshold level (20 IU/mL) in 4 of 60 (6.7%) AS patients. Anti-MCV levels are similar in patients with or without a -acceptable symptom state (PASS). There is also no appropriate anti-MCV cutoff level with respect to PASS and a highly sensitive and specific level for diagnosis of AS.
Although AS patients has higher anti-MCV levels than controls, it may have a limited ability to AS diagnosis and to predict severity of the disease.
强直性脊柱炎（AS）是一种具有严重发病率和死亡率的风湿性疾病。文献中的许多研究表明，类风湿关节炎（RA）患者体内抗突变瓜氨酸波形蛋白抗体（抗MCV抗体）水平可能升高。然而，关于AS患者抗MCV抗体水平的文献资料较少。我们设计了这项研究，以评估抗MCV抗体在AS诊断中的作用，并调查其是否与疾病活动参数相关。
我们的研究分为三个独立的组。这些组中的参与者数量分别为：AS组60例患者，RA组60例患者，对照组50名健康参与者。采用酶联免疫分析法测量参与者的抗MCV抗体水平。我们比较了各组之间的抗MCV水平。然后评估其在AS诊断中的作用，并评估其与疾病活动参数的关系。
发现AS患者（p = 0.006）和RA患者（p>0.001）的抗MCV抗体水平均显著高于对照组。60例AS患者中有4例（6.7%）的抗MCV抗体高于预定义阈值水平（20 IU/mL）。有或没有可接受症状状态（PASS）的患者抗MCV水平相似。关于PASS以及用于AS诊断的高敏感性和特异性水平，也没有合适的抗MCV临界值。
虽然AS患者的抗MCV水平高于对照组，但其在AS诊断和预测疾病严重程度方面的能力可能有限。
